Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Helix BioPharma Corp.TSX: HBP.TO
Other Current Liabilities · Q3 FY2026 · quarter ended Apr 2026
Other current liabilities remains negative
Q3 FY2026 other current liabilities was CA$3.67M, compared with CA$0 a year earlier.
Context
- Other current liabilities amounted to 17.2% of total assets at the end of Q3 FY2026, up 17.2 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
CAD · from the balance sheet
- Latest · FY2025
- 2.88M CAD
- Year-over-year change
- —
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 2.88M | — |
| FY2024 | 2024-07-31 | 0 | -100.0% |
| FY2023 | 2023-07-31 | 998K | +99900.0% |
| FY2022 | 2022-07-31 | (1K) | — |
| FY2021 | 2021-07-31 | 0 | — |
Other Current Liabilities vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Other current liabilities amounts to 17.2% of total assets for HBP.TO, versus a peer median of 16.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $13.71M USD | +51.1% | +20.1% | 10.5% | |
| Apr 2026 | CA$8.72M CAD | -55.9% | +23.0% | 568.4% | |
| Mar 2026 | CA$7.09M CAD | +20790.5% | +58.7% | 22.6% | |
| Apr 2026 | CA$3.67M CAD | — | — | 17.2% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $3.23K USD | — | — | 0.0% |
| Peer median (excluding HBP.TO) | — | +51.1% | +23.0% | 16.5% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.